Literature DB >> 19092786

Can hyperthyroidism relapse after antithyroid drug treatment be predicted in children with Graves disease?

Stephen A Huang1.   

Abstract

Entities:  

Year:  2008        PMID： 19092786     DOI： 10.1038/ncpendmet1042

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN： 1745-8366


× No keyword cloud information.
  7 in total

Review 1.  An optimal treatment for pediatric Graves' disease is radioiodine.

Authors:  Scott A Rivkees; Catherine Dinauer
Journal:  J Clin Endocrinol Metab       Date:  2007-03       Impact factor: 5.958

Review 2.  The optimal treatment for pediatric Graves' disease is surgery.

Authors:  James A Lee; Melvin M Grumbach; Orlo H Clark
Journal:  J Clin Endocrinol Metab       Date:  2007-03       Impact factor: 5.958

3.  Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group.

Authors:  O Törring; L Tallstedt; G Wallin; G Lundell; J G Ljunggren; A Taube; M Sääf; B Hamberger
Journal:  J Clin Endocrinol Metab       Date:  1996-08       Impact factor: 5.958

4.  High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.

Authors:  Erik K Alexander; P Reed Larsen
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

5.  Recurrence and morbidity in differentiated thyroid carcinoma in children.

Authors:  M P La Quaglia; M T Corbally; G Heller; P R Exelby; M F Brennan
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

6.  Surgical treatment of Graves' disease in children.

Authors:  Kiminori Sugino; Koichi Ito; Takashi Mimura; Nobuhiro Fukunari; Mitsuji Nagahama; Kunihiko Ito
Journal:  Thyroid       Date:  2004-06       Impact factor: 6.568

7.  Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment.

Authors:  Florentia Kaguelidou; Corinne Alberti; Mireille Castanet; Marie-Aline Guitteny; Paul Czernichow; Juliane Léger
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.